NASDAQ | VICL: 1.28  -0.03
investors
Investors

News Releases

DateSubject
December 5, 2012 Vical Licenses Vaxfectin(R) Adjuvant to Cyvax for Use in Malaria Vaccines
November 12, 2012 Vical to Present at Credit Suisse 2012 Healthcare Conference
November 8, 2012 Preclinical Data Support Potential Combinations for Allovectin(R) With Emerging Immunotherapies
November 7, 2012 Vical Reports Third Quarter 2012 Financial Results and Progress in Key Development Programs
November 2, 2012 Vical Names Mammen P. Mammen, Jr., M.D., Vice President, Clinical Vaccines
October 31, 2012 Vical Announces News Release and Conference Call Schedule for Third Quarter 2012 Financial Results
October 16, 2012 Vical Appoints George J. Morrow to Board of Directors
September 27, 2012 Vical to Present at 3rd Annual Cancer Immunotherapy Conference
September 13, 2012 Vical Licenses DNA Immunization Technology and Vaxfectin(R) Adjuvant to Bristol-Myers Squibb for Use in Antibody Production
August 29, 2012 Vical to Present at September Investor Conferences
August 6, 2012 Vical to Present at Canaccord Genuity Annual Growth Conference
August 1, 2012 Vical Reports Second Quarter 2012 Financial Results and Progress in Key Development Programs
July 25, 2012 Vical Announces News Release and Conference Call Schedule for Second Quarter 2012 Financial Results
July 5, 2012 Vical to Present at JMP Securities Healthcare Conference
June 13, 2012 Vical to Present at Wells Fargo Securities Healthcare Conference
May 22, 2012 Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data
May 16, 2012 Vical Updates Herpes Simplex Vaccine Development at ASGCT Conference
May 8, 2012 Vical to Present at Upcoming Investor Conferences
May 2, 2012 Vical Reports First Quarter 2012 Financial Results and Progress in Key Development Programs
April 25, 2012 Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results
April 2, 2012 Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical
March 28, 2012 Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant
March 5, 2012 U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin(R) Adjuvant
February 29, 2012 Vical to Present at Upcoming Investor Conferences
February 13, 2012 Vical to Present at Upcoming Investor Conferences
February 8, 2012 Vical Reports 2011 Financial Results and Progress in Key Development Programs
February 2, 2012 Vical Announces News Release and Conference Call Schedule for 2011 Financial Results
January 30, 2012 Vical Presents Case Study on Successful Design of Allovectin(R) Phase 3 Melanoma Trial
January 11, 2012 Vical Provides Updates on CMV Vaccine Programs
January 10, 2012 Vical to Present at Noble Financial Capital Markets Conference
January 6, 2012 Vical Incorporated Prices Public Offering of Common Stock
January 5, 2012 Vical Incorporated Announces Proposed Public Offering of Common Stock

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.